tender for e-tender for procurement of drug items under table-a, for two years from the date of aoc. , bupropion hydrochloride 150mg tab. , carboplatin inj. 450 mg./ vial , haloperidol tab. 0.25mg , insulin (human pre mixed ) soluble & nph combination (30 : 70) or (25:75)/ i.u. -in vial(maximum pack size allowed 10ml /vial) , insulin glargine (rdna 100 i.u./ml) -in vial / pfs/cartridge , insulin soluble inj. i.p.40 i.u. / ml in 10 ml vial . , nortriptyline 25mg tab. , zinc sulphate 20 mg. (dispersable) tab. , important note: 1. all prospective bidders are requested to quote the rate in boq as per accounting unit & item specification as mentioned in the table-a. wrong quoting of the rate in boq will be dealt with as per penal provisions of the t&c of the tender. 2. tendered quantity is just a tentative quantity and should not be treated as final. it may increase or decrease, as per need of the state. keeping this in mind, the supplier is not allowed to seek termination of the rate contract after finishing supply of tendered quantity. 3. quality of the product supplied, may be ascertained by testing / physical examination by the experts at any stage of the tender period. 4. the prospective bidders of the said tender are requested to make a declaration in affidavit under annexure vi(b) in case of sole manufacturer/importer (i.e. proprietary in nature). 5. if the item(s) under sole manufacturer / importer is (are) proprietary in nature, quarterly intimation is solicited from the approved bidders positively regarding the status of their item(s) proprietary in nature, otherwise their item(s) will be blocked in the smis. 6. in case of tie bid, decision will be taken by the tia as per g.o. no. 2320-f(y), dated 07.06.2022 issued from finance department audit branch (group t).